Neeraj Agarwal, MD, Huntsman Cancer Institute

home / authors / neeraj-agarwal-md-huntsman-cancer-institute

Articles

Future of Treating mRCC

Daniel J. George, MD, Duke Cancer Center;Neeraj Agarwal, MD, Huntsman Cancer Institute;Rana R. McKay, MD, University of California San Diego Medical Center;Sumanta K. Pal, MD, City of Hope Comprehensive Cancer Center
July 23rd 2020

Read More

Treating Patients With mRCC Beyond Second-Line

Treating Patients With mRCC Beyond Second-Line

Daniel J. George, MD, Duke Cancer Center;Neeraj Agarwal, MD, Huntsman Cancer Institute;Rana R. McKay, MD, University of California San Diego Medical Center;Sumanta K. Pal, MD, City of Hope Comprehensive Cancer Center
July 23rd 2020

Read More

Strategies for Switching From Frontline Therapy to Second-Line Therapy in mRCC

Strategies for Switching From Frontline Therapy to Second-Line Therapy in mRCC

Daniel J. George, MD, Duke Cancer Center;Neeraj Agarwal, MD, Huntsman Cancer Institute;Rana R. McKay, MD, University of California San Diego Medical Center;Sumanta K. Pal, MD, City of Hope Comprehensive Cancer Center
July 23rd 2020

Read More

Clinical Trials Shaping Treatment in Relapsed/Refractory mRCC

Clinical Trials Shaping Treatment in Relapsed/Refractory mRCC

Daniel J. George, MD, Duke Cancer Center;Neeraj Agarwal, MD, Huntsman Cancer Institute;Rana R. McKay, MD, University of California San Diego Medical Center;Sumanta K. Pal, MD, City of Hope Comprehensive Cancer Center
July 23rd 2020

Read More

Choosing Second-Line Therapy in Treatment of mRCC

Choosing Second-Line Therapy in Treatment of mRCC

Daniel J. George, MD, Duke Cancer Center;Neeraj Agarwal, MD, Huntsman Cancer Institute;Rana R. McKay, MD, University of California San Diego Medical Center;Sumanta K. Pal, MD, City of Hope Comprehensive Cancer Center
July 23rd 2020

Read More

Tailored Therapy Approaches for Upfront mRCC Treatment

Tailored Therapy Approaches for Upfront mRCC Treatment

Daniel J. George, MD, Duke Cancer Center;Neeraj Agarwal, MD, Huntsman Cancer Institute;Rana R. McKay, MD, University of California San Diego Medical Center;Sumanta K. Pal, MD, City of Hope Comprehensive Cancer Center
July 23rd 2020

Read More

Treating Side Effects of Therapy for mRCC with Steroids

Treating Side Effects of Therapy for mRCC with Steroids

Daniel J. George, MD, Duke Cancer Center;Neeraj Agarwal, MD, Huntsman Cancer Institute;Rana R. McKay, MD, University of California San Diego Medical Center;Sumanta K. Pal, MD, City of Hope Comprehensive Cancer Center
July 23rd 2020

Read More

Evaluating Safety Profiles of Upfront Regimens for mRCC

Evaluating Safety Profiles of Upfront Regimens for mRCC

Daniel J. George, MD, Duke Cancer Center;Neeraj Agarwal, MD, Huntsman Cancer Institute;Rana R. McKay, MD, University of California San Diego Medical Center;Sumanta K. Pal, MD, City of Hope Comprehensive Cancer Center
July 23rd 2020

Read More

Choosing Upfront Therapy for mRCC

Choosing Upfront Therapy for mRCC

Daniel J. George, MD, Duke Cancer Center;Neeraj Agarwal, MD, Huntsman Cancer Institute;Rana R. McKay, MD, University of California San Diego Medical Center;Sumanta K. Pal, MD, City of Hope Comprehensive Cancer Center
July 23rd 2020

Read More

CheckMate 9ER: Phase 3 Trial of Frontline Nivolumab + Cabozantinib

CheckMate 9ER: Phase 3 Trial of Frontline Nivolumab + Cabozantinib

Daniel J. George, MD, Duke Cancer Center;Neeraj Agarwal, MD, Huntsman Cancer Institute;Rana R. McKay, MD, University of California San Diego Medical Center;Sumanta K. Pal, MD, City of Hope Comprehensive Cancer Center
July 23rd 2020

Read More

Evaluating Long-Term Follow-Up Data for Treatment of mRCC

Evaluating Long-Term Follow-Up Data for Treatment of mRCC

Daniel J. George, MD, Duke Cancer Center;Neeraj Agarwal, MD, Huntsman Cancer Institute;Rana R. McKay, MD, University of California San Diego Medical Center;Sumanta K. Pal, MD, City of Hope Comprehensive Cancer Center
July 23rd 2020

Read More

Patient Factor Consideration for Treatment of mRCC

Patient Factor Consideration for Treatment of mRCC

Daniel J. George, MD, Duke Cancer Center;Neeraj Agarwal, MD, Huntsman Cancer Institute;Rana R. McKay, MD, University of California San Diego Medical Center;Sumanta K. Pal, MD, City of Hope Comprehensive Cancer Center
July 23rd 2020

Read More

Applying Clinical Trial Data for Treatment of mRCC

Applying Clinical Trial Data for Treatment of mRCC

Daniel J. George, MD, Duke Cancer Center;Neeraj Agarwal, MD, Huntsman Cancer Institute;Rana R. McKay, MD, University of California San Diego Medical Center;Sumanta K. Pal, MD, City of Hope Comprehensive Cancer Center
July 23rd 2020

Read More

Clinical Trials Defining the NCCN Guidelines for Frontline Treatment of mRCC

Clinical Trials Defining the NCCN Guidelines for Frontline Treatment of mRCC

Daniel J. George, MD, Duke Cancer Center;Neeraj Agarwal, MD, Huntsman Cancer Institute;Rana R. McKay, MD, University of California San Diego Medical Center;Sumanta K. Pal, MD, City of Hope Comprehensive Cancer Center
July 23rd 2020

Read More

Evaluation of Risk for Frontline Advanced/Metastatic Clear Cell RCC

Evaluation of Risk for Frontline Advanced/Metastatic Clear Cell RCC

Daniel J. George, MD, Duke Cancer Center;Neeraj Agarwal, MD, Huntsman Cancer Institute;Rana R. McKay, MD, University of California San Diego Medical Center;Sumanta K. Pal, MD, City of Hope Comprehensive Cancer Center
July 23rd 2020

Read More

Latest Updated Articles

Phase 1/2 ALKOVE-1 study of NVL-655 in ALK-positive (ALK+) solid tumors
Published: October 30th 2024 | Updated: November 7th 2024
Phase 1/2 ALKOVE-1 Study of NVL-655 in ALK-positive (ALK+) Solid Tumors
Updated Efficacy and Safety From the Phase 2 PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic NSCLC (mNSCLC)
Published: October 18th 2024 | Updated: October 21st 2024
Updated Efficacy and Safety From the Phase 2 PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic NSCLC (mNSCLC)
Daratumumab + Bortezomib/Lenalidomide/Dexamethasone in Patients With Transplant-ineligible or Transplant-deferred Newly Diagnosed Multiple Myeloma: Results of the Phase 3 CEPHEUS Study
Published: October 14th 2024 | Updated: October 16th 2024
Daratumumab + Bortezomib/Lenalidomide/Dexamethasone in Patients With Transplant-ineligible or Transplant-deferred Newly Diagnosed Multiple Myeloma: Results of the Phase 3 CEPHEUS Study
Phase 1 trial of DLL3/CD3 IgG-Like T-Cell Engager BI 764532 in Patients with DLL3 Positive Tumors: Patients with LCNEC
Published: September 27th 2024 | Updated: October 9th 2024
Petosemtamab Plus Pembrolizumab vs. Pembrolizumab Alone for First-Line (1L) Treatment of Recurrent/Metastatic (R/M) PD-L1–Positive Head and Neck Squamous Cell Carcinoma (HNSCC): A Randomized, Open-Label, Phase 3 Trial
Pooled Efficacy and Safety From 2 Pivotal Phase 2 Trials of Taletrectinib in Patients With Advanced or Metastatic ROS1+ Non–Small Cell Lung Cancer
Published: September 30th 2024 | Updated: October 4th 2024
Pooled Efficacy and Safety From 2 Pivotal Phase 2 Trials of Taletrectinib in Patients With Advanced or Metastatic ROS1+ Non–Small Cell Lung Cancer
Real world evidence of treatment practices and therapeutic outcomes for newly diagnosed NSCLC patients with non-classical EGFR mutations demonstrates high unmet medical need
Published: September 27th 2024 | Updated: October 4th 2024
Real World Evidence of Treatment Practices and Therapeutic Outcomes for Newly Diagnosed NSCLC Patients With Non-Classical EGFR Mutations Demonstrates High Unmet Medical Need